MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company, has announced the appointment of Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. Ahuja brings over 20 years of finance leadership experience, having most recently served as Vice President of Investor Relations at Agilent Technologies. His extensive background in financial operations, strategic financial planning and analysis, and investor relations positions him well to enhance MaxCyte's financial operations during a pivotal time for the company. CEO Maher Masoud expressed confidence in Ahuja's ability to support the company's growth and strategic priorities. Ahuja will receive an annual base salary of $450,000 and will be eligible for an annual cash performance bonus with an initial target of 50% of his base salary. Additionally, he will be granted stock options and restricted stock units as part of his compensation package. The company expects to enter into a severance agreement with Ahuja, which includes provisions for salary continuation and bonus payments in the event of termination without cause or resignation for good reason. This leadership change is expected to positively impact MaxCyte's operational execution and strategic outlook as it continues to advance its cell-engineering platform.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.